CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
CytomX Therapeutics (Nasdaq: CTMX) will report its third quarter 2025 financial results on Thursday, November 6, 2025, after the close of U.S. markets.
The company will host a conference call and live webcast on November 6, 2025 at 5:00 p.m. ET / 2:00 p.m. PT. Participants can access the live webcast via the company’s Events and Presentations page and are advised to register at least 10 minutes before the call. An archived replay of the webcast will be available on the company website.
CytomX Therapeutics (Nasdaq: CTMX) riferirà i suoi risultati finanziari del terzo trimestre 2025 giovedì 6 novembre 2025, dopo la chiusura dei mercati statunitensi.
L'azienda terrà una conference call e una webcast in diretta il 6 novembre 2025 alle 17:00 ET / 14:00 PT. I partecipanti possono accedere al webcast in diretta tramite la pagina Eventi e Presentazioni dell'azienda e si consiglia di registrarsi almeno 10 minuti prima della call. Una replica archiviata della webcast sarà disponibile sul sito web dell'azienda.
CytomX Therapeutics (Nasdaq: CTMX) reportará sus resultados financieros del tercer trimestre de 2025 el jueves 6 de noviembre de 2025, después del cierre de los mercados de Estados Unidos.
La empresa organizará una llamada de conferencia y una webcast en vivo el 6 de noviembre de 2025 a las 5:00 p.m. hora del Este / 2:00 p.m. hora del Pacífico. Los participantes podrán acceder al webcast en vivo a través de la página de Eventos y Presentaciones de la empresa y se les recomienda registrarse al menos 10 minutos antes de la llamada. Se dispondrá de una reproducción archivada de la webcast en el sitio web de la empresa.
CytomX Therapeutics (Nasdaq: CTMX)는 2025년 3분기 실적을 미국 시장 마감 후인 2025년 11월 6일 목요일에 발표합니다.
회사는 2025년 11월 6일 오후 5:00(Eastern Time) / 오후 2:00(Pacific Time)에 컨퍼런스 콜과 라이브 웹캐스트를 개최합니다. 참가자들은 회사의 이벤트 및 프리젠테이션 페이지를 통해 라이브 웹캐스트에 접속할 수 있으며, 전화 시작 최소 10분 전까지 등록하는 것이 권장됩니다. 웹캐스트의 보관 재생본은 회사 웹사이트에서 이용 가능합니다.
CytomX Therapeutics (Nasdaq: CTMX) annoncera ses résultats financiers du troisième trimestre 2025 le jeudi 6 novembre 2025, après la clôture des marchés américains.
La société organisera une conférence téléphonique et une diffusion en direct le 6 novembre 2025 à 17h00 HE / 14h00 PT. Les participants pourront accéder à la diffusion en direct via la page Événements et Présentations de la société et il est recommandé de s'inscrire au moins 10 minutes avant l'appel. Une rediffusion archivale de la diffusion sera disponible sur le site Web de la société.
CytomX Therapeutics (Nasdaq: CTMX) wird seine Ergebnisse zum dritten Quartal 2025 am Donnerstag, 6. November 2025 nach Börsenschluss in den USA bekannt geben.
Das Unternehmen wird am 6. November 2025 um 17:00 Uhr ET / 14:00 Uhr PT einen Conference Call und einen Live-Webcast veranstalten. Teilnehmer können den Live-Webcast über die Seite des Unternehmens Veranstaltungen und Präsentationen zugreifen und es wird empfohlen, sich mindestens 10 Minuten vor dem Anruf zu registrieren. Eine archivierte Wiedergabe des Webcasts wird auf der Website des Unternehmens verfügbar sein.
CytomX Therapeutics (Nasdaq: CTMX) ستعلن عن نتائجها المالية للربع الثالث من عام 2025 يوم الخميس 6 نوفمبر 2025، بعد إغلاق أسواق الولايات المتحدة.
ستعقد الشركة مكالمة مؤتمرات وبثًا مباشرًا في 6 نوفمبر 2025 الساعة 5:00 مساءً بالتوقيت الشرقي / 2:00 مساءً بالتوقيت الباسيفيكي. يمكن للمشاركين الوصول إلى البث المباشر عبر صفحة الأحداث والعروض التقديمية للشركة ويُنصح بالتسجيل قبل 10 دقائق على الأقل من المكالمة. ستكون هناك إعادة بث محفوظة للبث متاحة على موقع الشركة.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 6, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s multi-modality technology platform has produced therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. CytomX’s current clinical-stage pipeline includes CX-2051 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM), armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers, including CRC, and was discovered in collaboration with ImmunoGen. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com